1. Introduction {#sec1-ijms-18-01222}
===============

Drug hypersensitivity reactions (DHR) represent 5--10% of all adverse drug reactions \[[@B1-ijms-18-01222]\]. Longer inpatient stays and higher rates of hospital associated infections have been reported for antibiotic allergic patients \[[@B2-ijms-18-01222]\]. These reactions have multiple implications for patient safety and health system costs, often requiring alternative drugs to be prescribed; these alternative drugs may be less effective, more toxic and more expensive; moreover, in the case of antibiotics, this can augment the development of bacterial resistance \[[@B2-ijms-18-01222]\]. For these reasons, it is important to establish an accurate diagnosis of DHRs, and to avoid labeling tolerant individuals as allergic. However, it is just as important to correctly identify the responsible agent and find safe alternatives to avoid serious problems due to reactions. This is particularly important for severe DHR such as anaphylaxis, Steven--Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Although in theory drugs can induce the four types of reaction proposed in the Coombs and Gell classification \[[@B3-ijms-18-01222]\], types I and IV are the most frequent. Type I or immediate DHR (IDHR) are mediated by drug specific IgE (sIgE) antibodies attached to high-affinity IgE receptors, FcεRI, on mast cells or basophils, inducing release of mediators that lead to the reaction \[[@B3-ijms-18-01222]\]. Type IV or non-immediate DHR (NIDHR), are induced by T-cells through the involvement of different inflammatory mediators \[[@B4-ijms-18-01222]\]. Different reaction types show different clinical manifestations and timings, therefore mechanism should be taken into account during the allergological work-up.

The diagnostic procedure of a suspected DHR includes a detailed clinical history \[[@B5-ijms-18-01222]\], followed by skin tests (STs) \[[@B6-ijms-18-01222]\] and drug provocation testing (DPT) \[[@B7-ijms-18-01222]\]. This procedure can be complex, time-consuming, and expensive. Moreover, it can present some risk to the patient. A detailed clinical history is the most important step towards an accurate diagnosis of DHR. However, it can be unreliable since there may be a lack of accurate information, i.e., the chronology may be imprecise, the clinical manifestations may be heterogeneous and the exact name of drug or corrective treatment may be not recalled precisely by the patient, making drug causality assessment difficult to ascertain \[[@B8-ijms-18-01222]\].

Regarding STs, their diagnostic value is not well established for most drugs. Detailed, validated ST protocols for the diagnosis of DHR are lacking, and test concentrations are unknown or poorly validated. In many cases, STs have low sensitivity and require high drug concentrations; this can result in false-positive reactions due to the irritative properties of the drug. Moreover, many drugs are not available in injectable form and hence intradermal tests are not possible. Although STs are not validated and standardized for all drugs \[[@B6-ijms-18-01222],[@B9-ijms-18-01222]\], experts from both Europe and America suggest that it is possible to recommend specific drug concentrations for β-lactam (BLs) antibiotics, perioperative drugs, heparins, platinum salts, and radio contrast media (RCM) \[[@B9-ijms-18-01222]\].

Since clinical history can be unreliable and the sensitivity of STs may be suboptimal or unknown, the definitive diagnosis of DHR frequently relies upon DPT \[[@B10-ijms-18-01222]\]. DPT must be performed by controlled administration under medical surveillance. It is widely considered to be the gold standard to establish or exclude the diagnosis of hypersensitivity to a certain substance. It not only reproduces allergic symptoms but also any other adverse clinical manifestations, irrespective of the mechanism. Moreover, it can be used to provide alternative drugs \[[@B10-ijms-18-01222]\]. However, DPT is a procedure that consumes time and resources and, due to the possibility of reproducing the allergic reaction, is not risk free, especially when evaluating severe reactions. Therefore, it should be performed after balancing the risk--benefit ratio for each individual case. Patients at risk of more severe reactions should be given DPT in a hospital setting. It should not be performed in patients with co-morbidities such as acute infections or serious underlying diseases, as drug-exposure might provoke reactions that are hard to control. It should not be performed in patients who have experienced severe life-threatening reactions such as anaphylaxis, SJS or TEN \[[@B10-ijms-18-01222]\].

Given the low sensitivity of in vivo procedures, potential unreliability of clinical history, and riskiness of DPT, there is a clear need for the development of validated in vitro tests to aid and improve the diagnosis of DHR. These tests will help us to correctly identify the responsible agent for a reaction and evaluate cross-reactivity with other drugs, helping the physician to find safe alternatives, and reducing the need to perform DPT.

2. In Vitro Tests for the Diagnosis of Drug Hypersensitivity Reactions (DHR) {#sec2-ijms-18-01222}
============================================================================

Nowadays, in vitro methods for evaluating DHR depend on the underlying mechanism, whether IgE or T cell-mediated, and are mainly based on the analysis of drug sIgE or T cell subpopulations as well as the detection of specific markers after stimulation with the culprit drug and/or its metabolites.

As noted above, IDHR are IgE mediated. Therefore, the most widely used in vitro tests are immunoassays and basophil activation test (BAT). For NIDHR, which are cell-mediated, lymphocyte transformation tests (LTT), enzyme-linked immunosorbent spot assay (ELISpot), enzyme-linked immunosorbent assay (ELISA) and flow cytometry are typically used \[[@B11-ijms-18-01222],[@B12-ijms-18-01222]\]. However, there is high variability between published studies regarding their accuracy. This is likely due to small sample sizes, and in some studies the lack of appropriate control subjects. There is no general consensus regarding under which circumstances these tests are most appropriate. Recently, experts from the European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology provided recommendations regarding the available in vitro tests for DHR. They identified several unmet needs from which they highlighted the necessity to confirm the sensitivity, specificity, NPV and PPV for these in vitro tests. Such data are crucial to enable the implementation of in vitro testing in clinical practice, in order to reduce the need to perform DPT.

In this review, we have analyzed sensitivity and specificity as well as positive predictive value (PPV) and negative predictive value (NPV). Where possible, we have calculated these values using the data given in the studies. In total, we have obtained values from 60 publications, selecting studies that used in vitro test for evaluating DHR, for at least five patients. We have also estimated the added value of these tests to the in vivo diagnosis, paying special attention to how they can lead to increased ST sensitivity, avoiding the need to perform DPT.

3. IgE-Mediated Reactions {#sec3-ijms-18-01222}
=========================

The main goal of in vitro tests for these types of reaction is the determination of drug/drug metabolite sIgE, either soluble in serum, or bound to the basophil surface. However, since sIgE and especially drug sIgE are found at a very low concentration in the blood \[[@B13-ijms-18-01222]\], these in vitro methods must be highly sensitive. Another important issue is the need for different drugs to bind covalently to a carrier protein such as a hapten; this is required for a drug to induce an immune response. It is therefore important that the test includes the correct carrier molecules for appropriate IgE recognition \[[@B14-ijms-18-01222],[@B15-ijms-18-01222]\]. All these factors are critical for in vitro test development.

The most frequent methods to evaluate IDHR are immunoassays (radioimmunoassays and fluorimmunoassays) and tests based on basophil activation (BAT).

3.1. Immunoassays {#sec3dot1-ijms-18-01222}
-----------------

"Immunoassays" refers to a group of techniques that are based on the quantification of drug-sIgE present in patient sera. For this, the drug is conjugated to a carrier and coupled to a solid phase which is incubated with patient serum. If present, sIgE in the sera recognizes the drug, forming a drug-carrier-antibody complex which is quantified using a secondary anti-human IgE antibody labeled with a radioisotope (RIA) or a fluorescent enzyme (FEIA) \[[@B11-ijms-18-01222]\]. RIA is generally conducted using in house techniques, such as the radioallergosorbent test (RAST); FEIA can be performed using commercial products, such as the ImmunoCAP-FEIA, although such products are only available for few drugs \[[@B16-ijms-18-01222],[@B17-ijms-18-01222]\].

The majority of studies for evaluating the value of immunoassays for diagnosing IDHR have been performed with BLs \[[@B13-ijms-18-01222],[@B15-ijms-18-01222],[@B16-ijms-18-01222],[@B18-ijms-18-01222],[@B19-ijms-18-01222],[@B20-ijms-18-01222],[@B21-ijms-18-01222],[@B22-ijms-18-01222]\] and neuromuscular blocking agents (NMBAs) \[[@B23-ijms-18-01222],[@B24-ijms-18-01222],[@B25-ijms-18-01222],[@B26-ijms-18-01222],[@B27-ijms-18-01222],[@B28-ijms-18-01222],[@B29-ijms-18-01222]\], although a handful of studies have been carried out on other drugs, including chlorhexidine \[[@B30-ijms-18-01222]\], quinolones \[[@B31-ijms-18-01222],[@B32-ijms-18-01222]\] and biological agents \[[@B33-ijms-18-01222],[@B34-ijms-18-01222],[@B35-ijms-18-01222],[@B36-ijms-18-01222]\]. Many of these studies have included large numbers of allergic patients and controls, allowing us to estimate the sensitivity, specificity, PPV and NPV ([Table 1](#ijms-18-01222-t001){ref-type="table"}). Overall, we have calculated an average sensitivity of 62.9%, specificity of 89.2% and a PPV and NPV of 83.3% and 77.8%, respectively. In our opinion this sensitivity value is sub-optimal for clinical diagnosis, especially for BLs and no-BLs antibiotics. Moreover, NPV, the most useful parameter to decide whether to perform a DPT, is also relatively low \[[@B37-ijms-18-01222]\]. Interestingly, immunoassays show higher results for NMBAs, with sensitivity of 79.3%, specificity of 92.2% and PPV and NPV of 91.3% and 83.3%, respectively. Regarding biological agents, although the global sensitivity is low (48.2%), immunoassays show a high specificity (92.5%) and NPV (83.6%).

3.2. Basophil Activation Test {#sec3dot2-ijms-18-01222}
-----------------------------

This test is based on the determination of basophil activation or degranulation markers after drug stimulation using flow cytometry \[[@B17-ijms-18-01222],[@B38-ijms-18-01222]\]. Compared with the determination of sIgE by immunoassays, BAT analysis is used to demonstrate a functional response \[[@B37-ijms-18-01222]\]. BAT has been shown to be useful as an additional test for the diagnosis of DHR, especially for those cases where there are no other diagnostic tool available besides DPT. Basophils can be detected using a single cell marker, such as anti-IgE, CCR3, CRTH2, or CD203c, or a combination of several. Activation is usually assessed by determining the expression of CD63 or CD203c on the basophil surface \[[@B37-ijms-18-01222]\]. It is important to take into account that differences have been found in the upregulation of both markers depending on the drug tested and the clinical entity \[[@B39-ijms-18-01222],[@B40-ijms-18-01222]\]. When evaluating DHR using BAT, the possibility of activating basophils by a non-IgE-mediated mechanism exist, thus the involvement of the FcεRI-mediated pathway should be confirmed by inhibition with PI3Kinase inhibitors such as wortmannin \[[@B32-ijms-18-01222],[@B41-ijms-18-01222]\].

As for immunoassays, multiple studies with BAT using reasonable numbers of patients have been performed for BLs \[[@B18-ijms-18-01222],[@B19-ijms-18-01222],[@B39-ijms-18-01222],[@B42-ijms-18-01222],[@B43-ijms-18-01222],[@B44-ijms-18-01222],[@B45-ijms-18-01222]\] and NMBAs \[[@B24-ijms-18-01222],[@B25-ijms-18-01222],[@B46-ijms-18-01222],[@B47-ijms-18-01222],[@B48-ijms-18-01222],[@B49-ijms-18-01222],[@B50-ijms-18-01222],[@B51-ijms-18-01222]\]. Additional studies have been performed for fluoroquinolones (FQs) \[[@B31-ijms-18-01222],[@B40-ijms-18-01222],[@B52-ijms-18-01222],[@B53-ijms-18-01222]\], pyrazolones \[[@B54-ijms-18-01222],[@B55-ijms-18-01222],[@B56-ijms-18-01222]\] and RCM \[[@B57-ijms-18-01222],[@B58-ijms-18-01222]\] ([Table 2](#ijms-18-01222-t002){ref-type="table"}). The analyses of these studies, taken together, show an average sensitivity of 59.4%, specificity of 94.6% and PPV and NPV of 93.4% and 66.3%, respectively. Sensitivity and specificity are relatively similar for the different drugs, ranging from 51.7% to 66.9% and 89.2% to 97.8%, respectively. The lowest values of sensitivity and NPV have been found for BLs, being 51.7% and 49.9%, respectively. On the contrary, the highest sensitivity and NPV values were found for IDHR to FQs, 64.4% and 68.1%, respectively, and NMBAs, 66.9% and 72.1% respectively.

3.3. Combining In Vitro Tests for Evaluating Immediate Drug Hypersensitivity Reactions (IDHR) {#sec3dot3-ijms-18-01222}
---------------------------------------------------------------------------------------------

Several studies have performed both tests, immunoassays and BAT, for BLs \[[@B18-ijms-18-01222],[@B42-ijms-18-01222],[@B44-ijms-18-01222],[@B59-ijms-18-01222]\], FQs \[[@B31-ijms-18-01222]\] and NMBAs \[[@B24-ijms-18-01222],[@B25-ijms-18-01222]\]. We have used the data from these studies to estimate the diagnostic value obtained by combining the results of both tests. We found an overall mean in vitro sensitivity of 69.9% ([Figure 1](#ijms-18-01222-f001){ref-type="fig"}). Combining immunoassay + BAT results according to the culprit drug showed an increase in sensitivity of around 20%, for both BLs and NMBAs, compared to using only one test. In the only study performed in FQs, the inclusion of RIA had little effect compared to the results obtained with BAT alone ([Figure 2](#ijms-18-01222-f002){ref-type="fig"}a). The specificity of the combined in vitro tests was 90.9% which is in the range of the mean specificity of individual tests (89.2--94.6%).

3.4. Combining In Vitro and In Vivo Tests for Evaluating IDHR {#sec3dot4-ijms-18-01222}
-------------------------------------------------------------

We evaluated the sensitivity obtained when combining the results of both in vivo and in vitro tests, using studies that included ST data. We observed an increase from 65.7% when only in vivo tests are considered, to 75.9% when including both in vitro and in vivo tests ([Figure 1](#ijms-18-01222-f001){ref-type="fig"}). Combining in vivo and in vitro testing lead to an average increase of around 15% in sensitivity over in vivo testing alone for eight studies performed in BLs allergic patients \[[@B16-ijms-18-01222],[@B19-ijms-18-01222],[@B20-ijms-18-01222],[@B42-ijms-18-01222],[@B45-ijms-18-01222],[@B60-ijms-18-01222],[@B61-ijms-18-01222],[@B62-ijms-18-01222]\] as well as for other drugs such as NMBAs \[[@B24-ijms-18-01222],[@B48-ijms-18-01222]\], biological agents \[[@B34-ijms-18-01222],[@B36-ijms-18-01222]\], pyrazolones \[[@B55-ijms-18-01222],[@B56-ijms-18-01222]\] or RCM \[[@B57-ijms-18-01222],[@B58-ijms-18-01222]\] ([Figure 1](#ijms-18-01222-f001){ref-type="fig"} and [Figure 2](#ijms-18-01222-f002){ref-type="fig"}b). Regarding specificity, it was 91.8%.

It is interesting to note that in vitro tests, such as BAT, can produce positive results in IDHR patients who give negative STs; in fact 40% of ST negative patients with IDHR to BLs give positive BAT results \[[@B19-ijms-18-01222],[@B42-ijms-18-01222]\]; this figure is around 12% for FQs \[[@B53-ijms-18-01222]\] and 30% for pyrazolones \[[@B55-ijms-18-01222],[@B56-ijms-18-01222]\]. These results clearly indicate that the inclusion of in vitro tests complement the results of in vivo testing in the evaluation of IDHR, increasing the diagnostic sensitivity \[[@B24-ijms-18-01222]\]. However, we must take into account that in this test we can found 1--10% false positive results.

4. T Cell-Mediated Reactions {#sec4-ijms-18-01222}
============================

The evaluation of cell-mediated DHR or NIDHR is more complex than for IDHR, mainly due to the heterogeneity of clinical symptoms. These differences in symptoms imply that although in most reactions T cells are involved, many other cell subpopulations are likely to play a critical role \[[@B41-ijms-18-01222],[@B63-ijms-18-01222]\]. It is therefore important to study and characterize effector cells and their corresponding inflammatory mediators.

Most of the in vitro tests used for evaluating NIDHR have as their main goal the assessment of the drug involved in the reaction. The idea is to reproduce the effector reaction in vitro by activating T cells and inducing the appropriate inflammatory and cytotoxic mediator release that will be determined by LTT, ELISpot or ELISA. Most currently available studies for evaluating these types of reactions include small numbers of patients and have included a heterogeneous mix of patients and culprit drugs, generally including BLs, anticonvulsants, local anesthetic and NSAIDs. Another important limitation of these studies is that in most publications, the diagnosis has been confirmed by clinical history and/or STs and did not include DPT. Therefore, we cannot know if a patient would react to the drug. This limitation is compounded by the low sensitivity of STs in this type of reaction \[[@B64-ijms-18-01222]\].

4.1. Lymphocyte Transformation Test (LTT) {#sec4dot1-ijms-18-01222}
-----------------------------------------

This test is based on the determination of the lymphocyte proliferative response after stimulation with the specific drug \[[@B12-ijms-18-01222]\]. This proliferation has classically been measured via the incorporation of tritiated thymidine (^3^H) into the genome of proliferating cells and assessed by measuring the increase in radioactivity in a liquid scintillation counter system \[[@B38-ijms-18-01222]\]. With advances in flow cytometry, the possibility of assessing proliferation by the serial dilution of a fluorescent molecule (carboxyfluorescein diacetate succinimidyl ester (CFSE)) into the cells has appeared, introducing the possibility of identifying the effector cells involved in the reaction \[[@B11-ijms-18-01222]\]. However, there is a lack of studies comparing these two methods in terms of sensitivity and clinical value \[[@B17-ijms-18-01222]\].

We have analyzed the results of 13 studies \[[@B65-ijms-18-01222],[@B66-ijms-18-01222],[@B67-ijms-18-01222],[@B68-ijms-18-01222],[@B69-ijms-18-01222],[@B70-ijms-18-01222],[@B71-ijms-18-01222],[@B72-ijms-18-01222],[@B73-ijms-18-01222],[@B74-ijms-18-01222],[@B75-ijms-18-01222],[@B76-ijms-18-01222],[@B77-ijms-18-01222]\] of LTT containing at least five patients. We calculated a mean sensitivity of 56.1% and a specificity of 93.9%, while PPV and NPV were 92.3% and 63.2% respectively ([Table 3](#ijms-18-01222-t003){ref-type="table"}). Higher values were found when evaluating studies including mild and moderate reactions \[[@B65-ijms-18-01222],[@B66-ijms-18-01222],[@B67-ijms-18-01222],[@B68-ijms-18-01222],[@B69-ijms-18-01222],[@B70-ijms-18-01222],[@B71-ijms-18-01222],[@B72-ijms-18-01222]\], showing sensitivity and specificity values of 65.1% and 96.5% with PPV and NPV of 94.4% and 67.2%, respectively. However, these figures decreased when we only included severe reactions \[[@B73-ijms-18-01222],[@B74-ijms-18-01222],[@B75-ijms-18-01222],[@B76-ijms-18-01222],[@B77-ijms-18-01222]\], showing a sensitivity of 39.9%, specificity of 89.8% and PPV and NPV of 87.8% and 52.4%, respectively. These data suggest that LTT is better suited to evaluating moderate NIDHR compared to severe reactions, such as TEN and organ specific reactions \[[@B11-ijms-18-01222],[@B12-ijms-18-01222],[@B75-ijms-18-01222]\].

Moreover, some studies suggest that the sensitivity of the LTT for the diagnosis of NIDHR can be improved by including dendritic cells as antigen presenting cells \[[@B56-ijms-18-01222],[@B68-ijms-18-01222],[@B78-ijms-18-01222]\] as well as other innate factors that where involved in the original reaction \[[@B79-ijms-18-01222]\].

4.2. Enzyme-Linked Immunosorbent Spot (ELISpot) {#sec4dot2-ijms-18-01222}
-----------------------------------------------

ELISpot determines the number of cells producing an inflammatory marker, such as relevant cytokines and cytotoxic markers, after their activation by the specific drug \[[@B80-ijms-18-01222]\]. This method provides both qualitative and quantitative information and has demonstrated to be highly sensitive, enabling the detection of less than 25 secreting cells per 10^6^ peripheral blood mononuclear cells \[[@B17-ijms-18-01222],[@B38-ijms-18-01222]\]. It has been increasingly used for the evaluation of effector cells in NIDHR over the last decades \[[@B67-ijms-18-01222],[@B74-ijms-18-01222],[@B77-ijms-18-01222],[@B81-ijms-18-01222],[@B82-ijms-18-01222],[@B83-ijms-18-01222],[@B84-ijms-18-01222]\]. The six studies using ELISpot that have been included in this review are focused on BLs and/or anticonvulsants and measure the number of cells producing IFN-γ, IL-4, IL-5 or Granzyme B \[[@B67-ijms-18-01222],[@B76-ijms-18-01222],[@B77-ijms-18-01222],[@B85-ijms-18-01222],[@B86-ijms-18-01222],[@B87-ijms-18-01222]\]. Data showed a mean sensitivity of 61.2%, a specificity of 98.6, a PPV of 96.2% and a NPV of 59.1% ([Table 3](#ijms-18-01222-t003){ref-type="table"}).

4.3. Flow Cytometry and Enzyme-Linked Immunosorbent Assay (ELISA) {#sec4dot3-ijms-18-01222}
-----------------------------------------------------------------

Another approach for evaluating NIDHR after stimulation with the specific drug is by the determination of the cell activation and/or cytokines or cytotoxic production by either flow cytometry analysis of cells in culture or ELISA using the culture supernatants \[[@B72-ijms-18-01222],[@B79-ijms-18-01222],[@B88-ijms-18-01222],[@B89-ijms-18-01222],[@B90-ijms-18-01222],[@B91-ijms-18-01222],[@B92-ijms-18-01222]\]. These methodologies have been used for determining IL-2, IL-5, IL-10 and IFN-γ \[[@B74-ijms-18-01222],[@B93-ijms-18-01222]\]. We have included four studies that contained over five patients \[[@B74-ijms-18-01222],[@B93-ijms-18-01222],[@B94-ijms-18-01222],[@B95-ijms-18-01222]\], which found the mean sensitivity of these tests to be 66.6% and the specificity 87.5%, with PPV and NPV being 88.5% and 69.5%, respectively ([Table 3](#ijms-18-01222-t003){ref-type="table"}).

4.4. Combining In Vitro Tests for Evaluating Non-Immediate Drug Hypersensitivity Reactions (NIDHR) {#sec4dot4-ijms-18-01222}
--------------------------------------------------------------------------------------------------

Although the sensitivity of the above-mentioned tests for evaluating NIDHR showed a similar values ranging from 56.1 to 66.6% ([Table 3](#ijms-18-01222-t003){ref-type="table"}), it has been proposed that the combination of results from different assays could be useful \[[@B76-ijms-18-01222],[@B77-ijms-18-01222],[@B93-ijms-18-01222]\]. Different combinations have been reported, including LTT and a panel of cytokines/cytotoxic molecules determined by ELISpot, flow cytometry and/or ELISA (using IFN-γ, IL-2, IL-4, IL-5, granzyme B and granulysin) \[[@B67-ijms-18-01222],[@B74-ijms-18-01222],[@B76-ijms-18-01222],[@B77-ijms-18-01222],[@B85-ijms-18-01222],[@B93-ijms-18-01222]\]. Here, we have calculated the sensitivity of the combination of the results from different tests including data from those studies that performed at least two different in vitro methods. Results show an increase in sensitivity, up to 79.1% when evaluating patients with both moderate and severe NIDHR to betalactams and anticonvulsants ([Figure 3](#ijms-18-01222-f003){ref-type="fig"} and [Figure 4](#ijms-18-01222-f004){ref-type="fig"}). The specificity of the combined in vitro tests was 97.5% which is in the range of the specificity of individual tests (87.7--98.6%) ([Table 3](#ijms-18-01222-t003){ref-type="table"}).

These data indicate that the combination of different in vitro tests could help better identify the culprit drug in these types of reactions.

4.5. Combining In Vitro and In Vivo Tests for Evaluating NIDHR {#sec4dot5-ijms-18-01222}
--------------------------------------------------------------

We further analyzed the sensitivity of the allergological evaluation of NIDHR when the results of in vitro tests were combined with those obtained in in vivo (STs) tests and observed that it increases from 53.7% to 74.6% ([Figure 3](#ijms-18-01222-f003){ref-type="fig"} and [Figure 4](#ijms-18-01222-f004){ref-type="fig"}). This is very important if we take into account that many of these reactions show severe symptoms and that in many cases in vivo testing cannot be performed.

Interestingly, the mean sensitivity of in vitro tests (79.1%) is higher than those we have obtained when combining in vivo and in vitro results (74.6%), this is because different studies have been included in each case. Most studies that included in vivo sensitivity data used LTT as the in vitro test, which is relatively less sensitive. Thus, more studies including either ELISpot or ELISA/Flow cytometry in combination with skin testing should be performed in order to obtain a more accurate estimate of sensitivity for the in vivo/in vitro evaluation of NIDHR. Regarding specificity, it was 97.8%.

5. Conclusions {#sec5-ijms-18-01222}
==============

DHR diagnosis is a complex and unresolved issue due to the low sensitivity of the different approaches and the possible risks associated with performing DPT, especially for severe reactions, both for IDHR and NIDHR. The data presented in this review indicate that current in vitro methods, although not sufficient by themselves, can be helpful in assessing IDHR and NIDHR, and have been shown to increase the overall sensitivity of the diagnostic procedure when combined with in vivo testing.

They show, in general, a low sensitivity that depends on the drug involved and for those evaluating NIDHR also on the clinical manifestation. The low sensitivity could be related to other factors such as the use of non-appropriate drug metabolite(s) or drug-carrier conjugates that hide the relevant epitopes.

Cellular test has shown similar values of PPV and NPV independently of the type of reaction, IDHR or NIDHR. Additionally, it is important to note that, although NPVs are not optimal, in vitro tests have shown a good specificity, which correlates with a high PPV indicating that they could reduce the number of false positive results and help to decrease the administration of alternative drugs that, as mentioned before, could be less effective and induce undesired side effects. On the other hand, the low sensitivity could have serious effects when falsely labeling a patient as non-allergic, especially for severe reactions.

There is certainly room for improvement in in vitro testing. Areas requiring attention include: characterizing the drug metabolites involved in the reactions and that are recognized by the immunological system; characterizing the effector immunological mechanism involved in order to determine specific biomarkers; and combining results from multiple in vitro and in vivo tests.

Further studies are needed that include a large number of patients and controls and that take into account the combination of in vivo and in vitro tests in order to evaluate the real added value of the latter and therefore the possibility of avoiding the performance of drug provocation tests.
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![Bars represent the global sensitivity (mean plus standard deviation) for in vivo and in vitro tests alone or in combination for the evaluation of immediate drug hypersensitivity reactions (IDHR). BAT: Basophil activation test.](ijms-18-01222-g001){#ijms-18-01222-f001}

![(**a**) Bars represent the sensitivity of immunoassays (**white bars**), basophil activation test (BAT) (**light grey bars**) and immunoassay + BAT (**dark grey bars**) in individual studies performed with patients with IDHR to BLs, FQs or NMBAs; and (**b**) Bars represent the sensitivity of in vitro tests (including immunoassay and BAT) (**white bars**), in vivo tests (**light grey bars**) and combination of the results of both in vitro and in vivo tests (**dark grey bars**) in individual studies performed with patients with IDHR to different drug groups. BLs: β-lactams; FQ: Fluoroquinolones; NMBAs: Neuromuscular blocking agents; and RCM: Radio contrast media.](ijms-18-01222-g002){#ijms-18-01222-f002}

![Bars represent the global sensitivity of different in vivo and in vitro tests (mean plus standard deviation), either alone or in combination, for the evaluation of non-immediate drug hypersensitivity reactions (NIDHR).](ijms-18-01222-g003){#ijms-18-01222-f003}

![Bars represent the sensitivity of in vitro tests (**white bars**), in vivo tests (**light grey bars**) and combination of the results of both in vitro and in vivo tests (**dark grey bars**) in individual studies performed with NIDHR patients.](ijms-18-01222-g004){#ijms-18-01222-f004}
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###### 

Immunoassays in immediate reactions to different drugs.

  Paper                                         Patients           Drugs                                             Diag       Method     Sens (%)   Spec (%)   NPV (%)     PPV (%)
  --------------------------------------------- ------------------ ------------------------------------------------- ---------- ---------- ---------- ---------- ----------- ----------
  **Betalactams**                                                                                                                                                            
  Garcia 1997 \[[@B15-ijms-18-01222]\]          30 Pat 30 Cont     PG                                                ST         RAST       86.66      90         87.09       89.65
  Blanca 2001 \[[@B16-ijms-18-01222]\]          74 Pat 55 Cont     AX, PG                                            ST, DPT    CAP        50         96         58.8        94.4
  Sanz 2002 \[[@B18-ijms-18-01222]\]            58 Pat 30 Cont     PG, AX, AMP, CEFU, CEFAZ                          ST         CAP        37.9       86.7       41.9        84.6
  Garcia-Aviles 2005 \[[@B21-ijms-18-01222]\]   67 Pat 30 Cont     AX, PG CEFU, CEPHA                                ST, DPT    CAP        37.8       83.3       37.5        83.5
  Fontaine 2007 \[[@B20-ijms-18-01222]\]        30 Pat 15 Cont     AX, PG, AMP, CEFOT, CEFT, CEPH, CEFAC             ST, DPT    RAST       50         73.3       42.3        78.9
  CAP                                           16.6               93.3                                              35.9       83.2                                         
  De Weck 2009 \[[@B19-ijms-18-01222]\]         178 Pat 81 Cont    BP, AX, AMP, CEFs                                 ST, DPT    CAP        28.3       86.5       35.4        82.1
  Vultaggio 2009 \[[@B13-ijms-18-01222]\]       61 Pat 115 Cont    PG, PV, AX, AMP                                   ST         CAP        85         54         87.2        49.5
  Vultaggio 2015 \[[@B22-ijms-18-01222]\]       171 Pat 122 Cont   PG, PV, AX, AMP                                   ST         CAP        66         52         52.2        65.8
  CAP                                           43                 95                                                54.3       92.3                                         
  **Mean Values**                               **50.1**           **81.01**                                         **53.3**   **80.4**                                     
  **SD**                                        **23.0**           **16.2**                                          **19.6**   **13.5**                                     
  **Quinolones**                                                                                                                                                             
  Manfredi 2004 \[[@B32-ijms-18-01222]\]        55 Pat 32 Cont     CIPRO, LOME, NORFL, OFLO, PIP, RUFL, PEFL, NALI   CH         SEPH       54.5       100        56.1        100
  Aranda 2011 \[[@B31-ijms-18-01222]\]          38 Pat 25 Cont     CIPRO, MOXI, LEVO                                 CH, DPT    SEPH       31.6       100        49.0        100
  **Mean Values**                               **43.1**           **100**                                           **52.6**   **100**                                      
  **SD**                                        **16.19**          **0**                                             **5.0**    **0**                                        
  **NMBAs**                                                                                                                                                                  
  Guilloux 1992 \[[@B26-ijms-18-01222]\]        31 Pat 34 Cont     MOR, SUC, ALCU, TMA, TEA                          ST         RIA        96.7       97.2       96.9        96.9
  Mata 1992 \[[@B28-ijms-18-01222]\]            40 Pat 44 Cont     SUX, VECU, PANCU, ALCU, ATRAC, GALLA              CH, ST     SEPH       82.5       100        86.2        100
  Monneret 2002 \[[@B25-ijms-18-01222]\]        39 Pat 17 Cont     ROC, SUX, ATRAC                                   CH, ST     RIA        62         100        53.4        100
  Ebo 2007 \[[@B23-ijms-18-01222]\]             25 Pat 30 Cont     ROC, SUX, MOR, PHO                                ST         CAP        ROC: 92    ROC: 93    ROC: 93.3   ROC: 92
  SUX: 72                                       SUX: 100           SUX: 81.1                                         SUX: 100                                                
  MOR: 88                                       MOR: 100           MOR: 90.9                                         MOR: 100                                                
  PHO: 86                                       PHO: 100           PHO: 89.5                                         PHO: 100                                                
  Leysen 2011 \[[@B24-ijms-18-01222]\]          41 Pat 25 Cont     ROC                                               CH, ST     CAP        82.9       72.0       72.1        82.9
  Laroche 2011 \[[@B29-ijms-18-01222]\]         57 Pat 54 Cont     MOR                                               CH, ST     CAP        84.2       90.7       84.2        90.7
  Rouzaire 2012 \[[@B27-ijms-18-01222]\]        11 Pat 20 Cont     ROC, SUX, MOR                                     CH, ST     CAP        SUX: 44    SUX: 100   SUX: 76.4   SUX: 100
  ROC: 83                                       ROC: 68            ROC: 87.9                                         ROC: 59                                                 
  MOR: 78                                       MOR: 85            MOR: 87.5                                         MOR: 74                                                 
  **Mean Values**                               **79.3**           **92.2**                                          **83.3**   **91.3**                                     
  **SD**                                        **14.3**           **11.4**                                          **11.7**   **13.1**                                     
  **Clorhexidine**                                                                                                                                                           
  Garvey 2007 \[[@B30-ijms-18-01222]\]          12 Pat 10 Cont     CHLOR                                             ST         CAP        91.6       100        90.8        100
  **Biological Agents**                                                                                                                                                      
  Chung 2008 \[[@B33-ijms-18-01222]\]           26 Pat 512 Cont    CETUX                                             CH, DPT    CAP        68.0       98.0       98.4        63.3
  Vultaggio 2010 \[[@B34-ijms-18-01222]\]       11 Pat 20 Cont     INFLIX                                            CH         CAP        27.2       100        71.4        100
  Mariotte 2011 \[[@B35-ijms-18-01222]\]        14 Pat 195 Cont    CETUX                                             CH         ELISA      71.4       82.1       97.6        22.3
  Matucci 2013 \[[@B36-ijms-18-01222]\]         30 Pat 50 Cont     INFLIX                                            CH, ST     CAP        26.0       90.0       66.9        60.9
  **Mean Values**                               **48.2**           **92.5**                                          **83.6**   **61.6**                                     
  **SD**                                        **24.9**           **8.2**                                           **16.8**   **31.7**                                     

Pat: Patients; Cont: Controls; PG: Penicillin G; AX: Amoxicillin; AMP: Ampicillin; CEFU: Cefuroxime; CEFAZ: Cefazolin; CEFs: Cephalosporins; CEFOT: Cefotaxime; CEFT: Ceftriaxone; CEFAC: Cefaclor; PV: Penicillin V; CIPRO: Ciprofloxacin; LOME: Lomefloxacin; NORFLO: Norfloxacin; OFLO: Ofloxacin; PIP: pipemidic acid; RUFL: rufloxacin; PEFL: pefloxacin; NALI: nalidixic acid; MOXI: Moxifloxacin; LEVO: Levofloxacin; MOR: Morphine; SUC: succinylcholine; ALCU: Alcuronium; TMA: trimethylamine; TEA: triethylamine; SUX: sulfamethoxazole; VECU: vecuronium; PANCU: pancuronium; ATRAC: Atracurium; GALLA: gallamine; ROC: Rocuronium; PHO: pholcodine; CHLOR: Clorhexidine; CETUX: Cetuximab; INFLIX: Infliximab; Diag: Diagnostic method; ST: Skin test; DPT: Drug provocation test; CH: Clinical History; RAST: Radioallergosorbent test; CAP: ImmunoCAP-FEIA; SEPH: Sepharose; RIA: Radioimmunoassay; ELISA: Enzyme-linked immunosorbent assay; Sens: sensitivity; Spec: specificity; NPV: negative predictive value; PPV: positive predictive value; and SD: standard deviation.

ijms-18-01222-t002_Table 2

###### 

Basophil activation tests in immediate reactions to different drugs.

  Paper                                            Patients          Drugs                                                   Diag          Method     Sens (%)   Spec (%)   NPV (%)   PPV (%)
  ------------------------------------------------ ----------------- ------------------------------------------------------- ------------- ---------- ---------- ---------- --------- ---------
  **Betalactam**                                                                                                                                                                      
  Sanz 2002 \[[@B18-ijms-18-01222]\]               58 Pat 30 Cont    PG, AX, AMP, CEFU, CEFAZ                                ST            BAT        50         93.3       49.1      93.5
  Torres 2004 \[[@B42-ijms-18-01222]\]             70 Pat 40 Cont    PG, AX, AMP, CEFU, CEFAZ, CEFAC                         ST, DPT       BAT        48.6       93         50.8      92.4
  Abuaf 2008 \[[@B39-ijms-18-01222]\]              27 Pat 14 Cont    AX, AMP, CEFU                                           ST            BAT        63         79         52.5      85.2
  De Weck 2009 \[[@B19-ijms-18-01222]\]            178 Pat 81 Cont   BP, AX, AMP, CEFs                                       ST, DPT       BAT        48.3       88.9       43.8      90.5
  Torres 2010 \[[@B43-ijms-18-01222]\]             55 Pat 30 Cont    PG, AX, AX-CLV, CLV                                     ST            BAT        52.7       90         50.9      90.6
  Eberlein 2010 \[[@B44-ijms-18-01222]\]           24 Pat 15 Cont    PG, PV, AMP, AX, CEFU                                   ST            BAT        55         80         52.6      81.5
  Sanchez-Morillas 2010 \[[@B45-ijms-18-01222]\]   9 Pat 5 Cont      CLV                                                     ST, DPT       BAT        44.4       100        49.9      100
  **Mean Values**                                  **51.7**          **89.2**                                                **50.0**      **90.5**                                   
  **SD**                                           **6.0**           **7.5**                                                 **3.0**       **5.9**                                    
  **Fluoroquinolones**                                                                                                                                                                
  Aranda 2011 \[[@B31-ijms-18-01222]\]             38 Pat 25 Cont    CIPRO, MOXI, LEVO                                       CH, DPT       BAT        71.1       88         66.7      90.1
  Rouzaire 2012 \[[@B53-ijms-18-01222]\]           17 Pat 15 Cont    CIPRO, MOXI, LEVO, OFLOX, LOME, FLUME, NORFLO, PIPEMI   ST, DPT       BAT        76.5       100        78.9      100
  Mayorga 2013 \[[@B52-ijms-18-01222]\]            28 Pat 20 Cont    CIPRO, MOXI                                             CH, DPT       BAT        57.1       90         59.9      88.9
  Fernandez 2016 \[[@B40-ijms-18-01222]\]          17 Pat 18 Cont    CIPRO, MOXI                                             CH, DPT       BAT        52.9       88.9       66.7      81.8
  **Mean Values**                                  **64.4**          **91.7**                                                **68.1**      **90.2**                                   
  **SD**                                           **11.2**          **5.6**                                                 **7.9**       **7.5**                                    
  **NMBAs**                                                                                                                                                                           
  Abuaf 1999 \[[@B51-ijms-18-01222]\]              21 Pat 29 Cont    SUX, GALLA, VECU, PAN                                   CH, ST        BAT        64.0       93.0       78.1      86.9
  Monneret 2002 \[[@B25-ijms-18-01222]\]           39 Pat 17 Cont    ROC, SUX, ATRAC                                         CH, ST        BAT        54.0       100        48.6      100
  Sudheer 2005 \[[@B48-ijms-18-01222]\]            14 Pat 10 Cont    ROC, ATRAC, SUX, VECU                                   CH, ST        BAT        78.6       100        76.9      100
  Ebo 2006 \[[@B46-ijms-18-01222]\]                14 Pat 8 Cont     ROC                                                     ST            BAT        91.7       100        87.3      100
  Kvedariene 2006 \[[@B47-ijms-18-01222]\]         47 Pat 45 Cont    ROC, VECU, ATRA, PAN, SUX                               ST, DPT       BAT        36.1       93.3       58.3      84.9
  Leysen 2011 \[[@B24-ijms-18-01222]\]             41 Pat 25 Cont    ROC                                                     CH, ST        BAT        80.5       96.0       74.5      97.0
  Hagau 2013 \[[@B49-ijms-18-01222]\]              22 Pat 34 Cont    ATRAC, ROC, SUX, PAN                                    ST            BAT        68.2       100        82.9      100
  Uyttebroek 2014 \[[@B50-ijms-18-01222]\]         8 Pat 7 Cont      ATRA                                                    ST            BAT        62.5       100        70.0      100
  **Mean Values**                                  **66.9**          **97.8**                                                **72.1**      **96.1**                                   
  **SD**                                           **17.2**          **3.2**                                                 **12.9**      **6.4**                                    
  **Pyrazolones**                                                                                                                                                                     
  Gamboa 2003 \[[@B55-ijms-18-01222]\]             26 Pat 30 Cont    META                                                    ST, DPT       BAT        42.3       100        66.7      100
  Gomez 2009 \[[@B56-ijms-18-01222]\]              51 Pat 56 Cont    META                                                    CH, ST, DPT   BAT        54.9       85.7       65.1      79.6
  Hagau 2013 \[[@B54-ijms-18-01222]\]              20 Pat 10 Cont    DIP                                                     ST            BAT        65.0       100        58.8      100
  **Mean Values**                                  **54.1**          **95.2**                                                **63.5**      **93.2**                                   
  **SD**                                           **11.4**          **8.3**                                                 **4.2**       **11.8**                                   
  **Radio Contrast Media**                                                                                                                                                            
  Pinnobphun 2011 \[[@B57-ijms-18-01222]\]         26 Pat 43 Cont    IOXIT, IOPR, IOPA, IOH, IOB                             CH, ST        BAT        57.7       97.7       79.3      93.8
  Salas 2013 \[[@B58-ijms-18-01222]\]              8 Pat 20 Cont     IOD, IOH, IOM, IOB                                      ST, DPT       BAT        62.5       100        86.9      100
  **Mean Values**                                  **60.1**          **98.9**                                                **83.1**      **96.9**                                   
  **SD**                                           **3.4**           **1.6**                                                 **5.4**       **4.4**                                    

Pat: Patients; Cont: Controls; PG: Penicillin G; AX: Amoxicillin; AMP: Ampicillin; CEFU: Cefuroxime; CEFAZ: Cefazolin; CEFAC: Cefaclor; CEFs: Cephalosporins; CLV: Clavulanic acid; CIPRO: Ciprofloxacin; MOXI: Moxifloxacin; LEVO: Levofloxacin; OFLO: Ofloxacin; LOME: Lomefloxacin; FLUME: Flumequin; NORFLO: Norfloxacin; PIPEMI: Pipedimic acid; SUX: Suxamethonium; GALLA: gallamine; VECU: Vecuronium; PAN: Pancuronium; ROC: Rocuronium; ATRAC: Atracurium; META: Metamizole; DIP: Dipirone; IOXIT: Ioxithalamate; IOPR: Iopromide; IOPA: Iopamidol; IOH: Iohexol; IOB: Iobbitrol; IOD: Iodixanol; IOM: Iomeprol; Diag: Diagnostic method; CH: Clinical History; ST: Skin test; DPT: Drug provocation test; BAT: Basophil activation test; Sens: sensitivity; Spec: specificity; NPV: negative predictive value; PPV: positive predictive value; and SD: standard deviation.

ijms-18-01222-t003_Table 3

###### 

In vitro tests in non-immediate reactions to different drugs.

  Paper                                          Patients           Clinical Entity                    Drugs                       Diag       Method               Sens (%)                          Spec (%)                          NPV (%)                           PPV (%)
  ---------------------------------------------- ------------------ ---------------------------------- --------------------------- ---------- -------------------- --------------------------------- --------------------------------- --------------------------------- ---------------------------------
  **LTT**                                                                                                                                                                                                                                                                
  Roujeau 1985 \[[@B75-ijms-18-01222]\]          12 Pats 8 Cont     TEN                                Ant-Con, NSAID              CH         Thymidine            44.0                              63.0                              42.9                              64.1
  Nyfeler 1997 \[[@B70-ijms-18-01222]\]          100 Pat 102 Cont   ND                                 BLs                         CH, ST     Thymidine            74.4                              85.0                              77.2                              82.9
  Orasch 1999 \[[@B69-ijms-18-01222]\]           10 Pat 6 Cont      URT/ANG, EXANT                     LA                          CH, ST     Thymidine            60.0                              100                               60.0                              100
  Schnyder 2000 \[[@B66-ijms-18-01222]\]         12 Pat 6 Cont      EXANT                              BLs                         CH         Thymidine            83.3                              100                               74.9                              100
  Luque 2001 \[[@B71-ijms-18-01222]\]            19 Pat 28 Cont     URT, EXANT                         BLs                         ST, DPT    Thymidine            57.9                              92.8                              76.5                              84.5
  Hari 2001 \[[@B72-ijms-18-01222]\]             21 Pat 16 Cont     MPE, BULL-EXANT, URT               Ant-Con, Ant-hyp, others    CH         Thymidine            66.6                              93.8                              68.2                              93.4
  Sachs 2002 \[[@B74-ijms-18-01222]\]            10 Pat 10 Cont     MPE, AGEP, TEN                     BLs, Ant-Con                CH, ST     Thymidine            75.0                              100                               80.0                              100
  Rodriguez-Pena 2006 \[[@B68-ijms-18-01222]\]   9 Pat 8 Cont       MPE                                BLs                         CH, ST     Thymidine            22.2                              100                               53.3                              100
  \+ DC                                          88.8               100                                88.8                        100                                                                                                                                   
  Suzuki 2008 \[[@B73-ijms-18-01222]\]           69 Pat 50 Cont     BULL- EXANT, DILI                  Ant-tub                     CH, DPT    Thymidine            28.9                              90.7                              48.03                             81.1
  Rozieres 2009 \[[@B67-ijms-18-01222]\]         22 Pat 11 Cont     MPE                                BLs                         ST         Thymidine            68.2                              100                               61.1                              100
  Whitaker 2011 \[[@B65-ijms-18-01222]\]         28 Pat             URT/ANG, MPE, others               BLs                         CH         Thymidine            64.3                              ND                                ND                                ND
  Polak 2013 \[[@B77-ijms-18-01222]\]            43 Pat 14 Cont     MPE, DRESS, TEN, FDE, ECZ          Various                     CH         Thymidine            25.0                              95.1                              29.2                              94.0
  Porebski 2013 \[[@B76-ijms-18-01222]\]         15 Pat 18 Cont     SJS/TEN                            Ant-Con                     CH         Thymidine            26.6                              100                               62.0                              100
  **Mean Values**                                **56.1**           **93.9**                           **63.2**                    **92.3**                                                                                                                              
  **SD**                                         **22.7**           **10.4**                           **16.8**                    **11.1**                                                                                                                              
  **ELISpot**                                                                                                                                                                                                                                                            
  Rozieres 2009 \[[@B67-ijms-18-01222]\]         22 Pat 11 Cont     MPE                                BLs                         ST         IFN-γ                90.9                              100                               84.6                              100
  Polak 2013 \[[@B77-ijms-18-01222]\]            43 Pat 14 Cont     MPE, DRESS, TEN, FDE, ECZ          Various                     CH         IFN-γ, IL-4          IFNγ: 50.0 IL-4: 50.0             IFNγ: 82.9 IL-4: 92.0             IFNγ: 35.1 IL-4: 37.5             IFNγ:90.0 IL-4: 95.0
  Porebski 2013 \[[@B76-ijms-18-01222]\]         15 Pat 18 Cont     SJS/TEN                            Ant-Con                     CH         GranzymeB            33.3                              98.0                              63.8                              93.3
  Tanvarasethee 2013 \[[@B85-ijms-18-01222]\]    25 Pat 20 Cont     MPE                                BLs                         CH         IFN-γ, IL-5          40.0                              100                               57.1                              100
  Klaewsongkram 2016 \[[@B86-ijms-18-01222]\]    24 Pat 21 Cont     DRESS, SJS/TEN                     Allop                       CH         IFN-γ                79.2                              95.2                              80.0                              95.0
  Kato 2017 \[[@B87-ijms-18-01222]\]             16 Pat 3 Cont      EXANT, DRESS, TEN, SJS             Ant-Con                     CH         IFN-γ                85.0                              100                               55.5                              100
  **Mean Values**                                **61.2**           **98.6**                           **59.1**                    **96.2**                                                                                                                              
  **SD**                                         **23.3**           **6.3**                            **19.0**                    **3.9**                                                                                                                               
  **ELISA+Flow Cytomety**                                                                                                                                                                                                                                                
  Sachs 2002 \[[@B74-ijms-18-01222]\]            10 Pat 10 Cont     MPE, AGEP, TEN                     BLs, Ant-Con                CH, ST     IL-5, IFN-γ, IL-10   IL5: 91.6 IFNγ: 36.4 IL10: 50.0   IL5: 100 IFNγ: 60.0 IL10: 100     IL5: 92.3 IFNγ: 48.5 IL10: 66.7   IL5: 100 IFNγ: 47.6 IL10: 100
  Khalil 2008 \[[@B94-ijms-18-01222]\]           15 Pat 12 Cont     URT/ANG, MPE                       BLs                         ST         IL-2, IL-5, IFN-γ    IL-2: 86.7 IL-5: 100 IFNγ: 78.5   IL-2: 100 IL-5: 62.5 IFNγ: 90.0   IL-2: 85.7 IL-5: 100 IFNγ: 77.1   IL-2: 100 IL-5: 76.9 IFNγ: 90.8
  Halevy 2008 \[[@B95-ijms-18-01222]\]           12 Pat 11 Cont     VASC, URT, MPE, TEN, FDE, Others   Various                     CH         IFN-γ                80.0                              62.0                              74.0                              70.0
  Martin 2010 \[[@B93-ijms-18-01222]\]           19 Pat 10 Cont     URT, MPE, TEN, others              BLs, Ant-Con, RCM, others   CH         IL-2, IL-5, IFN-γ    IL2: 43.0 IL5: 43.0 IFNγ: 57.0    100                               IL2: 48.0 IL5: 48.0 IFNγ: 55.0    100
  **Mean Values**                                **66.6**           **87.5**                           **69.5**                    **88.5**                                                                                                                              
  **SD**                                         **23.2**           **18.2**                           **19.4**                    **18.1**                                                                                                                              

Pat: Patients; Cont: Controls; TEN: Toxic epidermal necrolysis; ND: Not determined; URT: Urticaria; ANG: Angioedema; EXANT: Exanthema; MPE: Maculopapular exanthema; BULL-EXANT: Bullous Exanthema; AGEP: Acute generalized exanthematic pustulosis; DILI: Drug induced liver injury; DRESS: Drug rash with eosinophilia and systemic symptoms; SJS: Stevens--Jonhson Syndrome; FDE: Fixed drug eruption; ECZ: Eczema; VASC: Vasculitis; Ant-Con: Anti-convulsant; NSAID: non-steroidal anti-inflammatory drugs; BLs: Betalactams; LA: Local Anesthetics; Ant-hyp: Anti-hyperthensive; Ant-tub: Anti-tuberculosis; Allop: Allopurinol; Diag: diagnostic method; CH: Clinical History; ST: Skin test; DPT: Drug provocation test; DC: Dendritic cells; Sens: Sensitivity; Spec: Specificity; NPV: Negative predictive value; PPV: Positive predictive value.
